Idorsia adds insomnia to its pipeline successes
Daridorexant scores in the first of two phase III insomnia studies, but attention will fall on a secondary endpoint measuring daytime performance.
Will Novo’s big thinking in obesity pay off?
Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.
Biohaven finds it hard to please in Covid times
A negative reaction to positive migraine data sends Biohaven down.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Zynerba hopes to crack fragile X at last
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
To challenge Ocrevus, German Merck takes on Aubagio
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
